FDA approves UroGen’s Zusduri to treat recurrent bladder cancer - PharmaTimes Approximately 59,000 LG-IR-NMIBC patients experience recurrent disease every year in the US

#bladdercancer #FDA #mitomycin #NMIBC #UroGenPharma #Zusduri #mitomycinintravesicalsolution #FDAapproved #LGIRNMIBC #LGIRNMIBCpatients #FoodandDrugAdministration #bladdercancerpatients #recurrentLGIRNMIBC #TURBT #bladdercancertreatment #ENVISIONclinicaltrial
pharmatimes.com/news/fda-app...

A medical professional in a white lab coat holds a digital illustration of a human bladder, symbolizing advanced urological care, with the company name UroGen Pharma represented.

Big win for #URGN: The FDA has approved ZUSDURI, the first and only non-surgical treatment for recurrent low-grade bladder cancer. A major step forward for patients facing repeat surgeries.
#UroGenPharma
prismmarketview.com/urogen-soars...